ArticleBMC pediatrics2025
Vitamin K2 deficiency associated with short stature in children: a cross-sectional study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundShort stature in children is a common concern that can result from various underlying conditions. While factors such as growth hormone deficiency and nutritional deficiencies are well-known contributors, the role of vitamin K2 (VK2) in the development of short stature remains underexplored. This study aimed to investigate the association between VK2 status and short stature in children.
methodsA total of 730 children aged 3-16 years were enrolled and divided into three groups: short stature group (n = 191), near-short stature group (n = 357), and normal stature group (n = 182). Clinical characteristics and growth-related indicators including serum VK2 levels, bone mineral density (BMD), insulin-like growth factor 1 (IGF-1), and 25-hydroxyvitamin D (25-(OH)D) were collected. VK2 was analyzed both as a categorical variable (VK2 deficiency vs. normal status) and as a continuous variable, logistic regression models were applied to assess the association between VK2 status and short stature using both approaches. Correlations between VK2 status and other growth-related indicators were also examined.
resultsThe prevalence of VK2 deficiency was higher in children with short stature (80.6%) and near-short stature (64.7%) compared to those with normal stature (32.4%) (P < 0.05). Multiple logistic regression models showed that higher serum VK2 levels were significantly associated with a decreased risk of short stature (aOR = 0.005, 95% CI: 0.001-0.036) and near-short stature (aOR = 0.023, 95% CI: 0.006-0.085); and VK2 deficiency was significantly associated with increased risk of short stature (aOR = 5.934, 95% CI: 3.372-10.443) and near-short stature (aOR = 3.233, 95% CI: 2.095-4.989) after adjusting for covariates. Additionally, serum VK2 levels were positively correlated with IGF-1-SDS and 25(OH)D (P < 0.05).
conclusionsVK2 deficiency was significantly associated with an increased risk of short stature in children. Further longitudinal studies are warranted to elucidate the causal relationship between VK2 deficiency and growth disorders in pediatric populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.